BR112022019685A2 - Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus - Google Patents

Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus

Info

Publication number
BR112022019685A2
BR112022019685A2 BR112022019685A BR112022019685A BR112022019685A2 BR 112022019685 A2 BR112022019685 A2 BR 112022019685A2 BR 112022019685 A BR112022019685 A BR 112022019685A BR 112022019685 A BR112022019685 A BR 112022019685A BR 112022019685 A2 BR112022019685 A2 BR 112022019685A2
Authority
BR
Brazil
Prior art keywords
sialic acid
inhibition
treatment
virus infections
corona virus
Prior art date
Application number
BR112022019685A
Other languages
English (en)
Portuguese (pt)
Inventor
Remmereit Jan
Original Assignee
Lifescience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifescience As filed Critical Lifescience As
Publication of BR112022019685A2 publication Critical patent/BR112022019685A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022019685A 2020-04-01 2021-03-31 Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus BR112022019685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003477P 2020-04-01 2020-04-01
PCT/IB2021/000200 WO2021198774A1 (en) 2020-04-01 2021-03-31 Sialic acid compositions for use in inhibiting and treating coronavirus infection

Publications (1)

Publication Number Publication Date
BR112022019685A2 true BR112022019685A2 (pt) 2022-11-22

Family

ID=76250375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019685A BR112022019685A2 (pt) 2020-04-01 2021-03-31 Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus

Country Status (8)

Country Link
US (3) US11813271B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125926A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520703A (cg-RX-API-DMAC7.html)
KR (1) KR20220161413A (cg-RX-API-DMAC7.html)
CN (1) CN115461057A (cg-RX-API-DMAC7.html)
AU (1) AU2021247584B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019685A2 (cg-RX-API-DMAC7.html)
WO (1) WO2021198774A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12667581B2 (en) 2020-06-09 2026-06-30 The Texas A&M University System Therapeutics for treatment of COVID-19 symptoms
CN118401246A (zh) 2021-12-09 2024-07-26 菲仕兰坎皮纳荷兰公司 抑制Covid-19感染的乳级分

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EP2364139A2 (en) * 2008-11-10 2011-09-14 Life Science Nutrition AS Ngna compositions and methods of use
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
US12685741B2 (en) * 2017-10-11 2026-07-21 Lifescience As N-acetylneuraminic acid compositions and methods of use
CN111481560A (zh) * 2020-04-23 2020-08-04 菌维他(北京)医疗科技有限公司 唾液酸及衍生物在制备防治冠状病毒疾病的药品中的应用
CN111658631A (zh) * 2020-06-11 2020-09-15 广东盛普生命科技有限公司 没食子酸及其衍生物和结构类似物在制备抗冠状病毒药物方面的应用

Also Published As

Publication number Publication date
US20260083762A1 (en) 2026-03-26
US20240148763A1 (en) 2024-05-09
JP2023520703A (ja) 2023-05-18
KR20220161413A (ko) 2022-12-06
AU2021247584A1 (en) 2022-10-20
WO2021198774A1 (en) 2021-10-07
US20230128687A1 (en) 2023-04-27
US12390481B2 (en) 2025-08-19
CN115461057A (zh) 2022-12-09
US11813271B2 (en) 2023-11-14
EP4125926A1 (en) 2023-02-08
CA3173633A1 (en) 2021-10-07
AU2021247584B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
PH12022552794A1 (en) Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022023013A2 (pt) Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19
JOP20220200A1 (ar) مركبات عالية النشاط ضد covid-19
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CO2020004087A2 (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas
BR0206266A (pt) Heterocìclicos de difenila substituìda útil para tratar infecção por hcv
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
CL2020002032A1 (es) Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325).
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112021020605A2 (pt) Inibidor de mek para o tratamento de infecções virais e bacterianas
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais